Jakafi ruxolitinib regulatory update

Germany's Federal Joint Committee (G-BA) said Jakavi ruxolitinib from Novartis has a "marginal" additional benefit for its approved indications of chronic myelofibrosis, post-polycythemia vera or essential thrombocythemia myelofibrosis. Novartis will now negotiate a price for the oral Janus kinase-1 (JAK-1) and JAK-2 inhibitor with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband). ...